NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
November 12, 2024 08:10 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
November 05, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
November 04, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
October 22, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 19, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
August 27, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
August 13, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Reports Second Quarter 2024 Financial Results
August 09, 2024 08:00 ET
|
NeurAxis, Inc.
Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
August 05, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
June 07, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...